Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27490413 | 0.88 | ALOX15 (0.48) | ALOX15NOTUMCA12CA1CA2 | |
| SCHEMBL1712040 | 0.84 | NOTUM (0.62) | ALOX15NOTUMCA12CA1CA2 | |
| SCHEMBL23866225 | 0.83 | NOTUM (0.56) | ALOX15NOTUMCA12CA1CA2 | |
| SCHEMBL30208027 | 0.83 | TAS1R3 (0.48) | NOTUMCA12CA1CA2CA9 | |
| SCHEMBL7472823 | 0.82 | ALOX15 (0.48) | ALOX15CA12CA1CA2CA9 | |
| SCHEMBL11090176 | 0.82 | ALOX15 (0.53) | ALOX15CA12CA1CA2CA9 | |
| SCHEMBL355461 | 0.81 | HDAC1 (0.51) | ALOX15CA12CA1CA2CA9 | |
| SCHEMBL38654909 | 0.81 | ALOX15 (0.47) | ALOX15CA12CA1CA2CA9 | |
| SCHEMBL3311471 | 0.80 | LMNA (0.54) | ALOX15NOTUMCA12CA1CA2 | |
| SCHEMBL30231213 | 0.79 | KIF11 (0.53) | ALOX15NOTUMCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-2390254-A1 | NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257678-A1 | VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF | INCEPT LLC (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016119-A1 | NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND | GPR119, GPR139, HCAR1 | ALOX15 2291/4885NOTUM 4248/4885CA12 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.